FDA’s ODAC Votes Against Risk:Benefit Profiles of Belantamab Mafodotin Combos in R/R Myeloma

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted against the risk/benefit profiles of belantamab mafodotin (Blenrep) in combination with bortezomib and dexamethasone (BVd), and with pomalidomide and dexamethasone (BPd), for relapsed/refractory multiple myeloma. Despite strong progression-free survival efficacy demonstrated in the Phase 3 DREAMM-7 and DREAMM-8 trials, the committee cited significant concerns over high rates of severe ocular toxicity (affecting 80-90% of patients, often unresolved), the lack of optimized dosing strategies, and the trials' limited applicability to the U.S. patient population. This decision, following the drug's prior voluntary withdrawal from the market, highlights the FDA's stringent focus on safety and dose optimization, even for active compounds in challenging diseases.

Analysis

The FDA's Oncologic Drugs Advisory Committee (ODAC) has delivered a significant setback for belantamab mafodotin, voting against the risk/benefit profile for two combination therapies in relapsed/refractory multiple myeloma. Despite demonstrating strong efficacy in the DREAMM-7 and DREAMM-8 trials, including a statistically significant improvement in progression-free survival (PFS)—where the BVd regimen showed a median PFS of 36.6 months versus 13.4 months for the control—the drug's path to approval is obstructed by severe safety concerns. The primary issue is the high rate of ocular toxicity, with 79% to 89% of patients experiencing ocular adverse events and a majority experiencing clinically meaningful vision reduction. The ODAC and FDA heavily criticized the developer for failing to conduct adequate dose optimization studies, leading to a proposed dosage with an unfavorable tolerability profile, a point explicitly cited as the rationale for the negative votes. This regulatory hurdle is compounded by concerns over the trial data's limited applicability to the US patient population due to demographic underrepresentation and evolving standards of care. This outcome echoes the drug's past commercial failure, where it was voluntarily withdrawn from the US market in 2022 after a confirmatory trial failed, likely due to similar tolerability issues.

Key Decisions for Investors

• The negative ODAC recommendation makes a near-term FDA approval for belantamab mafodotin in these indications highly improbable, creating a significant headwind for the asset's revenue potential.
• Investors should monitor for the developer's response, specifically any plans for new clinical trials focused on dose optimization, as this was the central critique and represents the only viable path forward for the drug.
• This regulatory failure strengthens the competitive position of other multiple myeloma treatments, particularly those with superior safety profiles, and casts serious doubt on the commercial viability of belantamab mafodotin in the crowded and evolving US market.